These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 32660751)

  • 1. Mechanisms of measles virus oncolytic immunotherapy.
    Pidelaserra-Martí G; Engeland CE
    Cytokine Growth Factor Rev; 2020 Dec; 56():28-38. PubMed ID: 32660751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus.
    Scheubeck G; Berchtold S; Smirnow I; Schenk A; Beil J; Lauer UM
    Viruses; 2019 Jul; 11(7):. PubMed ID: 31284426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measles Virus as an Oncolytic Immunotherapy.
    Engeland CE; Ungerechts G
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuated oncolytic measles virus strains as cancer therapeutics.
    Msaouel P; Iankov ID; Dispenzieri A; Galanis E
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1732-41. PubMed ID: 21740361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering and combining oncolytic measles virus for cancer therapy.
    Leber MF; Neault S; Jirovec E; Barkley R; Said A; Bell JC; Ungerechts G
    Cytokine Growth Factor Rev; 2020 Dec; 56():39-48. PubMed ID: 32718830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary resistance phenomena to oncolytic measles vaccine viruses.
    Noll M; Berchtold S; Lampe J; Malek NP; Bitzer M; Lauer UM
    Int J Oncol; 2013 Jul; 43(1):103-12. PubMed ID: 23612727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene.
    Yurttas C; Berchtold S; Malek NP; Bitzer M; Lauer UM
    Hum Gene Ther Clin Dev; 2014 Jun; 25(2):85-96. PubMed ID: 24933569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma.
    Lange S; Lampe J; Bossow S; Zimmermann M; Neubert W; Bitzer M; Lauer UM
    Hum Gene Ther; 2013 May; 24(5):554-64. PubMed ID: 23550539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
    Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
    PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses.
    Weiland T; Lampe J; Essmann F; Venturelli S; Berger A; Bossow S; Berchtold S; Schulze-Osthoff K; Lauer UM; Bitzer M
    Int J Cancer; 2014 Jan; 134(1):235-43. PubMed ID: 23797800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust envelope exchange platform for oncolytic measles virus.
    Neault S; Bossow S; Achard C; Bell JC; Diallo JS; Leber MF; Ungerechts G
    J Virol Methods; 2022 Apr; 302():114487. PubMed ID: 35104497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.
    Tan DQ; Zhang L; Ohba K; Ye M; Ichiyama K; Yamamoto N
    Eur J Immunol; 2016 Apr; 46(4):919-28. PubMed ID: 26763072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic measles virus strains as novel anticancer agents.
    Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
    Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy.
    Klose C; Berchtold S; Schmidt M; Beil J; Smirnow I; Venturelli S; Burkard M; Handgretinger R; Lauer UM
    BMC Cancer; 2019 Dec; 19(1):1172. PubMed ID: 31795974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies.
    Son HA; Zhang L; Cuong BK; Van Tong H; Cuong LD; Hang NT; Nhung HTM; Yamamoto N; Toan NL
    Cancer Invest; 2018 Feb; 36(2):106-117. PubMed ID: 29485292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies.
    Ekeke CN; Russell KL; Joubert K; Bartlett DL; Luketich JD; Soloff AC; Guo ZS; Lotze MT; Dhupar R
    Ann Surg Oncol; 2021 May; 28(5):2715-2727. PubMed ID: 33575873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Vaccine Strain Measles Virus and Nimotuzumab in the Treatment of Laryngeal Cancer.
    Toan NL; Hang NT; Luu NK; VAN Mao C; VAN Ba N; Xuan NT; Cam TD; Yamamoto N; VAN Tong H; Son HA
    Anticancer Res; 2019 Jul; 39(7):3727-3737. PubMed ID: 31262899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Susceptibility of Human Melanoma Cells to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
    Ammour Y; Ryabaya O; Shchetinina Y; Prokofeva E; Gavrilova M; Khochenkov D; Vorobyev D; Faizuloev E; Shohin I; Zverev VV; Svitich O; Nasedkina T
    Viruses; 2020 Feb; 12(2):. PubMed ID: 32033013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.